Figure 2.
Proportion of patients with DP over time in the OLEs. (A) EXTEND (MOBILITY/TARGET) and (B) MONARCH OLE. DP was defined as TJC28 − SJC28 ≥ 7. For MOBILITY and TARGET, data are shown only for patients who received sarilumab 200 mg
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.